Form 4: Jaguar Health CSO Boosts Stake with Stock and Options

Jaguar Health's CSO acquired 11,740 shares and options on December 11, 2025.

Summary

• Pravin R Chaturvedi, Chief Scientific Officer of Jaguar Health, Inc. (JAGX), acquired 11,740 shares of common stock.
• These shares were granted as restricted stock units (RSUs) under the issuer's 2014 Stock Incentive Plan.
• The restricted stock units are scheduled to vest on December 11, 2026.
• Chaturvedi also acquired 11,740 stock options with an exercise price of $1.44 per share.
• These options were granted under the 2014 Stock Incentive Plan and will vest ratably on a monthly basis over 12 months from the grant date of December 11, 2025.
• The stock options have an expiration date of December 11, 2035.
• The grants were approved by Jaguar Health's board of directors on December 11, 2025.
• On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of its issued and outstanding voting common stock.

Sentiment

Score: 7

Explanation: The filing reports an insider acquisition of equity and options, which is generally viewed as a positive signal, indicating management's confidence and alignment with shareholder interests. No negative information was disclosed.

Positives

• Chief Scientific Officer Pravin R Chaturvedi acquired 11,740 shares of common stock and 11,740 stock options, increasing insider ownership and aligning executive interests with long-term shareholder value.
• The equity grants were approved by the board of directors, indicating board confidence in the executive and the company's incentive structure.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports an insider transaction.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The restricted stock units are set to vest on December 11, 2026, and the stock options will vest ratably over 12 months from December 11, 2025, contingent on the executive's continued employment. This indicates an expectation of continued tenure for the Chief Scientific Officer and a long-term incentive structure.

Management Comments

• The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to incentivize and retain key executives like a Chief Scientific Officer. These grants align management's interests with long-term shareholder value, which is crucial in sectors with extensive research and development cycles.

Comparison to Industry Standards

• The use of restricted stock units and stock options for executive compensation is a common industry standard across publicly traded companies, particularly in sectors like biotechnology where long-term R&D cycles necessitate retention of key scientific talent.
• The vesting schedules (one year for RSUs, monthly over 12 months for options) are typical for performance-based or retention-based equity awards, aligning with common corporate governance practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholder value due to equity ownership. Potential future dilution from the exercise of stock options.
• Employees: Retention of a key executive (Chief Scientific Officer) through long-term equity incentives.

Next Steps

• Vesting of 11,740 restricted stock units on December 11, 2026, leading to the delivery of shares to the reporting person.
• Monthly vesting of 11,740 stock options over 12 months from December 11, 2025, contingent on continued employment.
• Potential future exercise of vested stock options by Pravin R Chaturvedi.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice. While insider ownership can be a positive signal, this transaction alone does not provide sufficient information to alter a fundamental investment thesis. Investors should consider this as a minor positive data point within a broader analysis of the company's financial performance and strategic outlook.

Keywords

Jaguar Health, JAGX, Pravin R Chaturvedi, Form 4, insider transaction, stock options, restricted stock units, equity compensation, Chief Scientific Officer, reverse stock split